Abstract library

966 results for "carcinoma of unknown primary".
#1285 Gastrointestinal Neuroendocrine Tumors of Unknown Primary Site: Report from a Series at a Single Institute
Introduction: Neuroendocrine neoplasms of unknown primary (NENs-UP) account for 10-13% of all NENs and show different biologic behavior, histologic appearance and clinical outcome.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: dr Sara Massironi
#633 Clinical and Prognostic Features of Neuroendocrine Tumor of Unknown Primary Site
Introduction: Neuroendocrine tumors of unknown primary site (NET UPS) are rare and heterogenous tumors with poor prognosis. There is little information available on the treatment and prognosis.
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: M.D., Ph.D. Hyun-Jeong Shim
Authors: Shim H J, Kim D, Hwang J E, Lee K H, ...
#167 Localization of Sporadic Neuroendocrine Tumors by Gene expression Analysis of Their Metastases
Introduction: Primary neuroendocrine tumors (NETs) are rare and often difficult to detect, leading to diagnosis late in their development. Cases in which the primary cannot be located are denoted as CUP-Syndrome.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dipl. Biol. Nicole Posorski
#694 Platinum-Based Chemotherapy for the Treatment of High-Grade Gastrointestinal and Unknown Primary Neuroendocrine Neoplasms
Introduction: Poorly differentiated neuroendocrine carcinomas (NEC sec. WHO 2010) are rare and aggressive neoplasms arising from different districts throughout the body. Platinum and etoposide regimen has been the most widely used first line treatment in this setting.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Marco Paragona
#2206 Metastatic Neuroendocrine Tumor with Unknown Primary Site Presenting Simultaneously with Prostate Adenocarcinoma
Introduction: Neuroendocrine tumors (NET) arise from a variety of different organs and have a steadily increasing incidence in the last 3 decades. 13% of NETs have unknown primary sites.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Oana-Stefana Enache
#285 A Case of Primary Hepatic Carcinoid Tumor Misdiagnosed as Hepatocellular Carcinoma (HCC)
Introduction: Carcinoid tumors generally occur in the gastrointestinal and respiratory tracts. Primary carcinoid tumor of the liver is very rare. It may be misdiagnosed as hepatocellular carcinoma, which is very common.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Jila Hazrati
#684 Clinical Characteristics and Survival of Neuroendocrine Tumors of Unknown Primary
Introduction: NETs of unknown primary account for 10-15% of NETs. There is limited published literature on this group of NETs.
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: Dr Raj Srirajaskanthan
#141 Incidence of second primary tumors in patients with neuroendocrine tumors
Introduction: Based on epidemiological data from SEER 1950-1999, 22.4% cases of non-carcinoid second primary tumors have been described in patients diagnosed with neuroendocrine tumors. The incidence of this type of tumors varies, depending on the series assessed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Juan Manuel OConnor
Authors: Pesce V, OConnor J, Mendez G, Bestani C, ...
#1095 Efficacy of Topotecan in Pretreated Metastatic Neuroendocrine Carcinoma
Introduction: Therapeutic options for metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC) after prior platinum-based chemotherapy are limited. Topotecan is an approved second line chemotherapy for small cell lung cancer (SCLC) which is often considered to show a biological behavior similar to NEC.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. med. Leonidas Apostolidis
#681 The Use of Capsule Endoscopy for Assessment of Neuroendocrine Tumors of Unknown Primary Tumor Location
Introduction: Recent studies suggest that capsule endoscopy (CE) should be implemented in diagnostic work-up in patients suspected to have small bowel (SB) tumors. SB accounts for the primary tumor site in 80%-85% of patients with intestinal neuroendocrine tumors (NET). In 10%-15% of patients diagnosed with metastasized NET, the primary tumor site remains obscure.
Conference: 10th Annual ENETS Conference (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: PhD Panagiotis Drymousis